TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Boosted by Vanguard Group Inc.

Vanguard Group Inc. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTXFree Report) by 0.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,471,174 shares of the biopharmaceutical company’s stock after acquiring an additional 16,074 shares during the period. Vanguard Group Inc. owned about 8.90% of TG Therapeutics worth $112,619,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Advisor Group Holdings Inc. raised its stake in shares of TG Therapeutics by 49.5% during the 1st quarter. Advisor Group Holdings Inc. now owns 34,433 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 11,406 shares in the last quarter. Raymond James & Associates increased its holdings in TG Therapeutics by 4.3% in the first quarter. Raymond James & Associates now owns 165,994 shares of the biopharmaceutical company’s stock worth $1,579,000 after buying an additional 6,860 shares during the last quarter. HighTower Advisors LLC raised its position in TG Therapeutics by 28.3% during the first quarter. HighTower Advisors LLC now owns 13,603 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,998 shares in the last quarter. MetLife Investment Management LLC lifted its stake in TG Therapeutics by 59.0% in the first quarter. MetLife Investment Management LLC now owns 71,269 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 26,443 shares during the last quarter. Finally, BlackRock Inc. grew its position in TG Therapeutics by 0.4% in the first quarter. BlackRock Inc. now owns 8,935,578 shares of the biopharmaceutical company’s stock worth $84,978,000 after acquiring an additional 33,413 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the transaction, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Laurence N. Charney sold 17,500 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $19.03, for a total transaction of $333,025.00. Following the completion of the sale, the director now owns 237,229 shares of the company’s stock, valued at approximately $4,514,467.87. The disclosure for this sale can be found here. 9.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TGTX shares. B. Riley lifted their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Monday, February 5th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of TG Therapeutics in a research report on Wednesday, February 28th. StockNews.com downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Finally, The Goldman Sachs Group raised their price objective on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $26.17.

Check Out Our Latest Stock Report on TGTX

TG Therapeutics Trading Up 0.2 %

TG Therapeutics stock opened at $14.47 on Thursday. TG Therapeutics, Inc. has a 52 week low of $6.46 and a 52 week high of $35.67. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The firm has a market capitalization of $2.23 billion, a PE ratio of 723.86 and a beta of 2.30. The business’s 50-day simple moving average is $15.43 and its 200-day simple moving average is $13.49.

TG Therapeutics (NASDAQ:TGTXGet Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The company had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. During the same period in the previous year, the business posted ($0.39) EPS. Equities research analysts forecast that TG Therapeutics, Inc. will post -0.12 earnings per share for the current year.

TG Therapeutics Profile

(Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Featured Articles

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.